<DOC>
	<DOCNO>NCT00662805</DOCNO>
	<brief_summary>Primary objective : Evaluation safety Seretide discus administration subject COPD . Treatment duration : 2 year . Study 3 phase : Screening phase ( visit 1 ) , treatment phase ( visits 2-5 . In case AE , another visit ( visit 6 ) follow visit - follow phase .</brief_summary>
	<brief_title>Pharmacovigilance Study Evaluate Safety SERETIDE Participants With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Subject fulfill criterion subscription SERETIDE mention SPC . Hypersensitivity Salmeterol + Fluticasone excipients Pregnancy , lactation schedule pregnancy observational period study Serious illness/disease , adequately control , potential interfere patient ' participation present study , accord investigator/physician 's judgment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>pharmacovigilance</keyword>
	<keyword>COPD</keyword>
</DOC>